Assessing Brexpiprazole for Schizophrenia and Depression
Official title: Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders: a Naturalistic Non-interventional Prospective Follow-up Study
Run by The University of Hong Kong · NCT05962216 · Data updated 2026-11-12
This study is testing how well brexpiprazole works and how easy it is to tolerate for adults with schizophrenia or depression who have just started taking the medication.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Status | Recruiting |
| Started | July 1, 2023 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | July 8, 2025 |
| Trial ID | NCT05962216 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-65 who have recently started treatment with brexpiprazole for psychosis or as an adjunct for major depressive disorder.
✕Probably not a fit
Patients under 18 years old or those unable to provide informed consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study evaluates the real-life efficacy and tolerability of brexpiprazole in adult patients diagnosed with psychotic disorders or major depressive disorder. Participants aged 18-65 who have been prescribed brexpiprazole for less than four weeks will be monitored over a six-month period. The study aims to gather data on the drug's performance in a naturalistic setting, focusing on its benefits and side effects. Minimal exclusion criteria are applied to reflect typical clinical practice.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness and safety of brexpiprazole for treating schizophrenia and depression.
How similar studies have gone: Other studies have shown promise in evaluating the efficacy of second-generation antipsychotics like brexpiprazole, suggesting that this approach is supported by existing research.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: 18- 65 years old at the time of enrollment * Able to read and communicate in English and/or Chinese * Able to give informed consent * Has been diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), or International Statistical Classification of Diseases and Related Health Problems 10th revision (ICD-10) to have either Psychotic Disorders (F10-F19.5, F20-23, F25, F32-F33) * is receiving brexpiprazole as treatment for less than 4 weeks at the time of recruitment Exclusion Criteria: * Age \<18 years old * Unable to read English or Chinese * Unable to give informed consent * Had been diagnosed to have Intellectual Disabilities (DSM-5) or Mental Retardation (ICD-10 F70-73)
Where it's running
-
Queen Mary Hospital
Hong Kong, Hong Kong Recruiting
Study contacts
- Study coordinator: Albert KK Chung, MBBS
- Email: Chungkka@hku.hk
- Phone: 2255 4486
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Examining the effects of combined therapy for schizophrenia
This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.
-
Improving mental health care in West Africa using mobile health and nurse support
This study is testing whether a new approach that combines nurse support and a mobile health app can improve mental health care for people with serious mental illnesses in Ghanaian prayer camps.
-
Effects of Estradiol on Depression and Psychosis in Perimenopausal Women
This study tests if giving estradiol to women aged 44-55 who are going through perimenopause can help improve their depression and psychosis symptoms.
-
Smartphone-supported single-session psychotherapy for postpartum depression
A single online therapy session plus four weeks of app-based support is being tested to see if it reduces depressive symptoms in postpartum women compared with a waitlist.
-
Mindful Smartphone Use: A Mindfulness-Based Program for Teens with Sleep and Mood Challenges
This study tests Mindwire, a mindfulness-based program, to see if it helps teens with problematic phone use who also have depression or anxiety.
-
Tele-based wellbeing centres for women's mental health in Bangladesh
A randomized trial tests whether tele-counselling for depression and anxiety in Bangladeshi women is as effective as in-person counselling.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.